Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

5.170 +0.430 (+9.07%)
Official Closing Price Updated: 4:10 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Key Takeaways From Emergent BioSolutions Analyst Ratings
Via Benzinga
Looking Into Emergent BioSolutions's Recent Short Interest
Via Benzinga
How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings
American Express offers an annual dividend yield of 1.12%, or $2.80 a year. How can investors pocket a regular $500 monthly? 
Via Benzinga
Watch These 4 Overbought Stocks As Market Rotation Continues
Recent market rotations and sector-specific outflows have created a ripe environment for potential pullbacks despite the market's 17% YTD gain. 
Via MarketBeat
Topics ETFs
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
JNJ to release 2Q financial results on July 17. Expected earnings $2.70/share, revenue $22.29B. Investors eye 3.32% dividend yield for gains. 
Via Benzinga
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71. 
Via Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration. 
Via Benzinga
Exposures COVID-19
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
From Emergent BioSolutions
Via GlobeNewswire
Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?
Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health and Human Services. The funding ensures the supply of critical medical... 
Via Benzinga
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
7 Top Stocks Under $10: June 2024 Edition
While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification. 
Via InvestorPlace
What Is Going On With Emergent BioSolutions Shares?
On Thursday prior to the market open, Emergent BioSolutions announced it entered into a definitive agreement with Bora to sell the site for about $30 million. 
Via Benzinga
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
7 Stocks to Buy Immediately Following Strong Earnings
These stocks to buy after earnings look good following especially strong earnings prints at each respective company in Q1. 
Via InvestorPlace
Vice Stock Vanguards: 3 Sin Stocks Delivering Heavenly Returns
While it might not feel right, consider these three sin stocks to buy, since the money is there to be made one way or another. 
Via InvestorPlace
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
From Emergent BioSolutions
Via GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper highlights five stocks each week that are seeing increased attention from readers and partners. 
Via Benzinga
Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171.08%. 
Via Benzinga
Nasdaq Gains Over 200 Points; Dentsply Sirona Shares Fall After Q1 Results
Via Benzinga
Dow Surges Over 100 Points; ConocoPhillips Earnings Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
MercadoLibre Stock Split: Will MELI Investors See Wishes Come True Today?
MercadoLibre stock is up on Thursday as investors are hoping a split for MELI shares will be announced after markets close today. 
Via InvestorPlace
JPMorgan Just Raised Its Price Target on Carvana (CVNA) Stock
Carvana stock is climbing higher on Thursday after shares of CVNA got an increased price target and upgrade from JPMorgan analyst Rajat Gupta. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.